Company: IPSC
Filing Date: 2025-12-02
Form Type: DEF 14A
Source: 0001104659-25-117704
Chunk: 15

Company: Century Therapeutics, Inc.
Filing Date: 2025-12-02
Form: DEF 14A
Chunk 15
---
 | ​ | ​ |                                       3,959,420 | ​ | ​ |                     791,884 | ​ | ​ |                      395,942 | ​ | ​ |                      197,971 | ​ | ​ |                      131,980 | ​ | ​ |
| ​ | ​ | Common stock reserved for issuance for future grants under our 2021 Employee Stock Purchase Plan           | ​ | ​ |                                         639,745 | ​ | ​ |                     127,949 | ​ | ​ |                       63,974 | ​ | ​ |                       31,987 | ​ | ​ |                       21,324 | ​ | ​ |
| ​ | ​ | Common stock authorized but unissued and unreserved/unallocated                                            | ​ | ​ |                                     202,813,287 | ​ | ​ |                 288,562,659 | ​ | ​ |                  299,281,331 | ​ | ​ |                  304,640,666 | ​ | ​ |                  306,427,113 | ​ | ​ |

The Reverse Stock Split will affect all of our stockholders uniformly and will not materially affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. The Reverse Stock Split will not change the terms of our Common Stock. The shares of new Common Stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the Common Stock now authorized (other than as a result of the payment of cash in lieu of fractional shares). For example, a holder of 2% of the voting power of the outstanding shares of our Common Stock immediately prior to a Reverse Stock Split would continue to hold 2% of the voting power of the outstanding shares of our Common Stock immediately after such Reverse Stock Split. The number of stockholders of record will not be affected by a Reverse Stock Split (except to the extent that any stockholder holds only a fractional share interest and receives cash for such interest after such Reverse Stock Split). The Common Stock issued pursuant to the Reverse Stock Split will remain fully paid and non-assessable. After the Split Effective Time, our Common Stock will have a new Committee on Uniform Securities Identification Procedures (“CUSIP”) number, which is a number used to identify our equity securities. The Reverse Stock Split is not intended as, and will not have the effect of, a “going private transaction” covered by Rule 13e-3 under the Securities Exchange Act of 1934, as amended (the “